rosiglitazone has been researched along with naveglitazar in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Agejas, J; Alt, CA; Ardecky, R; Briere, DA; Brooks, DA; Brozinick, JT; Dolores Martín-Ortega, M; Ferritto, R; Fraser, JD; González, R; Hawkins, E; Lamas, C; López de Uralde, B; Martín, JA; Misener, EA; Montrose-Rafizadeh, C; Parra, F; Prieto, L; Reifel-Miller, A; Rhodes, GA; Rizzo, JR; Robey, RL; Rojo, I; Torrado, A; Warshawsky, AM; Wendel, SR; Zhang, TY | 1 |
| Kagechika, K; Kubo, H; Shibata, Y; Usui, H; Yamaguchi, M | 1 |
2 other study(ies) available for rosiglitazone and naveglitazar
| Article | Year |
|---|---|
2-Alkoxydihydrocinnamates as PPAR agonists. Activity modulation by the incorporation of phenoxy substituents.
Topics: Animals; Blood Glucose; Cinnamates; Diabetes Mellitus, Type 2; Disease Models, Animal; Dose-Response Relationship, Drug; Peroxisome Proliferator-Activated Receptors; Rats; Rats, Zucker; Structure-Activity Relationship; Triglycerides | 2005 |
Design, synthesis and evaluation of novel zwitterionic compounds as PPARα/γ dual agonists (1).
Topics: Animals; Blood Glucose; Drug Design; Mice; PPAR alpha; PPAR gamma; Structure-Activity Relationship; Thiazolidinediones; Triglycerides; Weight Gain | 2012 |